5 news items
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
SCNI
15 May 24
contract discussions with several other potential clients. We expect revenues from the CDMO business to increase materially in the coming years due
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
SCNI
6 May 24
cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
SCNI
8 Apr 24
, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics
Scinai leadership to attend BIO-Europe Spring 2024
SCNI
12 Mar 24
to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
SCNI
29 Feb 24
materially from those expected by the management of Scinai Immunotherapeutics
- Prev
- 1
- Next